Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Predicting Survival Outcomes in Patients With Acute Myeloid Leukemia: Medium-Sized Versus Large Next-Generation Sequencing Panels

American Association for Cancer Research

AACR 2023 Annual Meeting

Orlando FL, April 14-19, 2023

Poster presentation: Predicting survival outcomes in patients with acute myeloid leukemia: medium-sized versus large next-generation sequencing panels

Authors: Li Y,  Solis-Ruiz J, Racke FK, Press RD

Specialties: Oncology

Related content

Publication
Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation
On-Demand Webinar
Unwinding with DDX41 A case presentation regarding DDX41 and its germline predisposition to myeloid neoplasms
On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML
On-Demand Webinar
Hemepath Master Class: Chronic lymphocytic leukemia CLL small lymphocytic lymphoma SLL
Conference Presentation
Trial in progress: Comprehensive outcomes for after cancer health (COACH), a randomized trial assessing health outcomes following primary cancer therapy

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.